Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

ASCO 2022 | Areas of unmet need for DLBCL: primary refractory disease and double-hit lymphoma

Tycel Phillips • 5 Jun 2022
ASCO 2022
Diffuse Large B-Cell Lymphoma Lymphoma Non-Hodgkin Lymphoma R-CHOP

Tycel Phillips, MD, University of Michigan, Ann Arbor, MI, discusses areas of unmet needs for patients with diffuse large B-cell lymphoma (DLBCL), drawing focus on patients with primary refractory disease who do not respond to standard of care treatment. In addition, Dr Phillips highlights double-hit lymphoma, an aggressive type of B-cell non-Hodgkin lymphoma characterized by translocations involving MYC, and BCL-2 or BCL-6, and are associated with a poor prognosis when treated with standard chemoimmunotherapy. This interview took place at the American Society of Clinical Oncology (ASCO) 2022 Annual Meeting in Chicago, IL.

More from Tycel Phillips

0:51
An update from ASH 2023: advancements in NHL treatment
Tycel Phillips • 10 Dec 2023
1:54
A retrospective analysis of real-world data from patients treated for R/R follicular lymphoma
Tycel Phillips • 10 Dec 2023
1:55
Optimal sequencing of CAR-T and bispecifics in NHL
Tycel Phillips • 10 Dec 2023
1:17
GLOBRYTE: investigating glofitamab monotherapy in patients with R/R MCL
Tycel Phillips • 10 Dec 2023

Related Videos

2:04
Salvage treatment options following CAR-T failure in DLBCL
Jaromir Tomasik • 17 Apr 2024
1:55
Exploring first-line CAR-T therapy for the treatment of DLBCL
Wendy Osborne • 22 Apr 2024
3:29
CAR-T therapy as the SoC in 2L LBCL and barriers that remain
Wendy Osborne • 22 Apr 2024
2:11
The role of CAR-T therapy for lymphoma in 2024: expert session highlights
Sridhar Chaganti • 16 Apr 2024
The content of VJHemOnc is intended for healthcare professionals